AstraZeneca Not Immune To ‘Expected’ China Slowdown
This article was originally published in PharmAsia News
Like a number of other pharma multinationals, AstraZeneca's sales growth in China slowed in the second quarter, but the UK-based firm says this was expected and that it still foresees a double digit increase in the country over the rest of the year.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.